Definitive Contract 75F40120C00140

This is a Definitive Contract awarded by the Food and Drug Administration (FDA) to Weill Medical College of Cornell University, a prestigious private research university. The contract, valued at $994,896.00, is for the development of rabbit animal models of ventilator-associated bacterial pneumonia produced by Carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. This work is being conducted under Broad Agency Announcement (BAA) 19-00123, PMWP#132. The contract has a firm fixed-price pricing type and a completion date of June 30, 2023. No set-aside designation was used for this award. Weill Medical College of Cornell University, the prime contractor, is a leading academic medical center that has a strong track record of securing federal funding for medical research and clinical trials. The parent organization, Cornell University, is a private research institution and 1862 Land Grant College that provides a wide range of services to the federal government through contract and grant awards.